Decision making about operability in non-small cell lung cancer

Area of Science:

• Thoracic Surgery
• Oncology
• Pulmonology

Background:

• Combined modality therapy and advanced staging techniques are redefining surgical resection for non-small cell lung cancer (NSCLC).
• The primary goal of surgical intervention in lung cancer is achieving complete tumor resection, even following neoadjuvant or induction therapy.

Purpose of the Study:

• To outline the current indications and evolving role of surgical resection in the management of non-small cell lung cancer.
• To emphasize the importance of precise staging and complete resection in optimizing patient outcomes.

Main Methods:

• Review of current clinical guidelines and surgical practices for non-small cell lung cancer.
• Discussion of staging criteria, including peroperative and pathological assessment of tumor and nodal involvement.
• Evaluation of lymph node dissection techniques and the challenges of post-induction surgery.

Main Results:

• Definite surgical indications include clinical stages I, II, and resectable IIIA non-small cell lung cancer.
• The role of surgery in stage IIIA-N2 non-small cell lung cancer is controversial and limited to downstaged patients.
• Systematic nodal dissection of at least three hilar and three mediastinal lymph node stations is recommended.
• Downstaging is a critical prognostic factor, with persistent mediastinal lymph node involvement indicating a poor prognosis.

Conclusions:

• Complete resection remains the ultimate goal in surgical treatment for non-small cell lung cancer, particularly after neoadjuvant therapy.
• Accurate staging, including pathological proof of nodal status, is essential for surgical decision-making.
• While remediastinoscopy is feasible, research into less invasive restaging methods is ongoing.